Bjørn Tore Gjertsen, MD, PhD. is Professor of Hematology from 2007 at Department of Clinical Science at the University of Bergen, working as Research Chief and Consultant Hematologist at Helse Bergen Health Trust, developing early phase clinical trials at Haukeland University Hospital. In 2016 Gjertsen was appointed co-director for Centre for Cancer Biomarkers (CCBIO) Norwegian Centre of Excellence, University of Bergen. His major research interest is development of targeted therapy and accompanying diagnostics in the aggressive blood cancer acute myeloid leukemia. His laboratory is working on intracellular signal transduction and its regulation of the tumor suppressor protein p53. Single cell signaling and immune profiling by multiplexing mass cytometry has been developed for monitoring of immuno- and signaling-directed therapy and is currently used for therapy development of various cancers and myeloid leukemias.

2025

• Mariano Sanz; Cecilie Gjerde; Bjørn Tore Gjertsen et al. (2025). Bone Augmentation of Atrophic Alveolar Ridges Using a Synthetic Bone Substitute With Mesenchymal Stem Cells: A Randomized, Controlled Clinical Trial. (ekstern lenke)
• Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2025). High-dimensional Immune Profiling Following Autologous Hematopoietic Stem Cell Transplantation in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Titas Gladkauskas; Ileana Cristea; Roya Mehrasa et al. (2025). Temperature as a Key Modulator: Investigating Phosphorylation Patterns of p.Asn666 PDGFRB Variants and Their Role in Downstream Signaling. (ekstern lenke)
• Sonja Loges; Michael Heuser; Jörg Chromik et al. (2025). Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial. (ekstern lenke)
• Lok Lam Ngai; Tom Reuvekamp; Diana Hanekamp et al. (2025). Different features of acute myeloid leukemia stem cell quantification in intensively treated patients. (ekstern lenke)
• Gandhar K. Datar; Elmira Khabusheva; Archish Anand et al. (2025). Disparate leukemia mutations converge on nuclear phase-separated condensates. (ekstern lenke)

1991

• M. Lanotte; J. B. Riviere; S. Hermouet et al. (1991). Programmed cell death (apoptosis) is induced rapidly and with positive cooperativity by activation of cyclic adenosine monophosphate-kinase I in a myeloid leukemia cell line. (ekstern lenke)
• Ragnar Bøe; Bjørn Tore Gjertsen; G. Houge et al. (1991). The protein phosphatase inhibator okadaic acid induces morphological changes typical of apoptosis in mammalian cells. (ekstern lenke)

2017

• Sieghart Sopper; Satu Mustjoki; Bjørn Tore Gjertsen et al. (2017). NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. (ekstern lenke)
• S Laukkanen; T Grönroos; P Pölönen et al. (2017). In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. (ekstern lenke)
• Misbah Sabir; Monica Hellesøy; Jarno Kivioja et al. (2017). development of novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia. (ekstern lenke)
• Stein-Erik Gullaksen; Jørn Skavland; Sonia Gavasso et al. (2017). Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. (ekstern lenke)
• Bob Lowenberg; Thomas Pabst; Johan Maertens et al. (2017). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. (ekstern lenke)
• Sieghart Sopper; Satu Mustjoki; Deborah White et al. (2017). Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. (ekstern lenke)
• Vibeke Andresen; Bjørn Tore Gjertsen (2017). Drug Repurposing for the Treatment of Acute Myeloid Leukemia. (ekstern lenke)
• Spiros Kotopoulis; Endre Stigen; Mihaela Lucia Popa et al. (2017). Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. (ekstern lenke)
• Mika Kontro; Anil Kumar; Muntasir Mamun Majumder et al. (2017). HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. (ekstern lenke)
• Håkon Reikvam; Randi Hovland; Rakel Brendsdal Forthun et al. (2017). Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. (ekstern lenke)
• Maria del Pilar Ayuda-Duran; B Zhang; L. Piechaczyck et al. (2017). a precision medicin platform for acute myeloid leukemia to help unraveling the molecular addictions of FLT3-ITD-driven AML. (ekstern lenke)
• Rakel Brendsdal Forthun; Elise Aasebø; Josef Daiel Rasinger et al. (2017). Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. (ekstern lenke)
• Riikka Karjalainen; Mihaela Lucia Popa; M Liu et al. (2017). Stroma-derived factors stimulate JAK/STAT signaling in AML cells resulring in resistance to BCL2 inhibitor Venetoclax. (ekstern lenke)
• Nina Louise Jebsen; Samantha Scarlett; Bergrun Tinna Magnusdottir et al. (2017). Biomarker Panels and Contemporary Practice in Clinical Trials of Targeted Therapy. (ekstern lenke)

2007

• Bjarte Skoe Erikstein; Karl Johan Tronstad; Emmet Martin McCormack et al. (2007). Synergistic anti-leukemic effect of protein kinase a activator and PPAR7agonist is independent of Bcl-2 status. (ekstern lenke)
• Line Wergeland; Eystein Oveland; Gry Sjøholt et al. (2007). Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. (ekstern lenke)
• Tien-Sheng Huang; Line Merethe Myklebust; Endre Kjærland et al. (2007). LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. (ekstern lenke)
• Emmet Martin McCormack; David Robert Micklem; Lars Erik Pindard et al. (2007). In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. (ekstern lenke)
• Øystein Bruserud; Camilla I Stapnes; Elisabeth Ersvær et al. (2007). Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. (ekstern lenke)
• Gurid Venaas; Emmet Martin McCormack; Ingvild Haaland et al. (2007). In vivo optical imaging of p53 specific targeted therapy in Acute Myeloid Leukaemia. (ekstern lenke)
• Elisabeth Silden; Emmet Martin McCormack; David Robert Micklem et al. (2007). Development of a near infrared reporter system for in vivo imaging. (ekstern lenke)
• Nina Ånensen; Anne Margrete Øyan; Sjur Huseby et al. (2007). Early gene expression of acute myeloid leukemia in response to chemotherapy. (ekstern lenke)
• Emmet Martin McCormack; Alexandre Belankov; Maja Mujic et al. (2007). Discrimination and quantification of spectrally similar near-infrared probes by time-domain (TD) optical imaging in acute myeloid leukemia mouse models. (ekstern lenke)
• Anne Margrete Øyan; Trond Hellem Bø; Inge Jonassen et al. (2007). Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. (ekstern lenke)
• Jonathan C. Irish; Nina Ånensen; Randi Hovland et al. (2007). Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. (ekstern lenke)
• Tien-Sheng Huang; Line Merethe Myklebust; Endre Kjærland et al. (2007). LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. (ekstern lenke)
• Emmet Martin McCormack; David Robert Micklem; Lars Erik Pindard et al. (2007). In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. (ekstern lenke)
• Øystein Bruserud; Camilla I Stapnes; Elisabeth Ersvær et al. (2007). Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. (ekstern lenke)
• Gurid Venaas; Emmet Martin McCormack; Ingvild Haaland et al. (2007). In vivo optical imaging of p53 specific targeted therapy in Acute Myeloid Leukaemia. (ekstern lenke)
• Elisabeth Silden; Emmet Martin McCormack; David Robert Micklem et al. (2007). Development of a near infrared reporter system for in vivo imaging. (ekstern lenke)
• Camilla I Stapnes; Anita Ryningen; Kimberley Joanne Hatfield et al. (2007). Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. (ekstern lenke)
• Bjørn Tore Gjertsen; Therese Bredholt; Nina Ånensen et al. (2007). Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. (ekstern lenke)
• Line Wergeland; Eystein Oveland; Gry Sjøholt et al. (2007). Flt3 Mutations in Proximity to an Ubiquitin Dependent Endocytosis Motif Suspend Its Hdm2 Modulation. (ekstern lenke)
• F Parlati; M Aujay; Siv Lise Bedringaas et al. (2007). Anti-Tumor Activity of Immunoproteasome Selective Inhibitors. (ekstern lenke)
• Francesco Parlati; Monette Aujay; Siv Lise Bedringaas et al. (2007). Anti-tumor activity of immunoproteasome selective inhibitors. (ekstern lenke)
• Elisabeth Ersvær; Peter Hampson; Kimberley Joanne Hatfield et al. (2007). T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. (ekstern lenke)
• Camilla I Stapnes; Anne Paulus Døskeland; Kimberley Joanne Hatfield et al. (2007). The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. (ekstern lenke)
• Camilla I Stapnes; Anita Ryningen; Kimberley Joanne Hatfield et al. (2007). Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. (ekstern lenke)
• Emmet Martin McCormack; Alexandre Belankov; Maja Mujic et al. (2007). Discrimination and Quantification of Spectrally Similar Near-Infrared Probes by Time-Domain (TD) Optical Imaging in AML models. (ekstern lenke)
• Maja Mujic; Emmet Martin McCormack; Anita Ryningen et al. (2007). Development and evaluation of labeled antibodies as optical contrast reagents in acute myeloid leukemia (AML). (ekstern lenke)
• Line Wergeland; Bjørn Tore Gjertsen; Øystein Bruserud (2007). Flt3 receptor tyrosine kinase in AML and its modulation of the p53/Hdm2/Bcl-2 pathway. (ekstern lenke)
• Kjell Petersen; Anne Margrete Øyan; Kari Rostad et al. (2007). Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. (ekstern lenke)
• Anne Margrete Øyan; Nina Ånensen; Trond Hellem Bø et al. (2007). Early gene expression signature of chemotherapy treated acute myeloid leukemia in vivo. (ekstern lenke)

2006

• Anne Margrete Øyan; Trond Hellem Bø; Inge Jonassen et al. (2006). cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. (ekstern lenke)
• Camilla I Stapnes; Anita Ryningen; Bjørn Tore Gjertsen et al. (2006). Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. (ekstern lenke)
• Nina Ånensen; Bjørn Tore Gjertsen (2006). p53 protein biosignatures in acute myeloid leukemia. (ekstern lenke)
• Øystein Bruserud; Karl Johan Tronstad; Emmet Martin McCormack et al. (2006). Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?. (ekstern lenke)
• Nina Ånensen; Anne Margrete Øyan; Jean-Christophe Bourdon et al. (2006). A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. (ekstern lenke)
• Werner Van Belle; Nina Ånensen; Ingvild Haaland et al. (2006). Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. (ekstern lenke)
• Anne Margrete Øyan; Nina Ånensen; Trond Hellem Bø et al. (2006). The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. (ekstern lenke)
• Nina Ånensen; Bjørn Tore Gjertsen (2006). p53 protein biosignatures in acute myeloid leukemia. (ekstern lenke)
• Øystein Bruserud; Karl Johan Tronstad; Emmet Martin McCormack et al. (2006). Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?. (ekstern lenke)
• Eystein Oveland; Kari Espolin Fladmark; Line Wergeland et al. (2006). Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. (ekstern lenke)
• Øystein Bruserud; Camilla I Stapnes; Karl Johan Tronstad et al. (2006). Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. (ekstern lenke)
• Anne Margrete Øyan; Trond Hellem Bø; Inge Jonassen et al. (2006). cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. (ekstern lenke)
• Camilla Krakstad; Lars Herfindal; Bjørn Tore Gjertsen et al. (2006). CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. (ekstern lenke)
• Gry Sjøholt; Siv Lise Bedringaas; Anne Paulus Døskeland et al. (2006). Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). (ekstern lenke)
• Werner Van Belle; Gry Sjøholt; Nina Ånensen et al. (2006). Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment. (ekstern lenke)
• Nina Ånensen; Jørn Skavland; Camilla I Stapnes et al. (2006). Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. (ekstern lenke)
• Anne Margrete Øyan; Nina Ånensen; Trond Hellem Bø et al. (2006). The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. (ekstern lenke)
• Anne Margrete Øyan; Trond Hellem Bø; Inge Jonassen et al. (2006). cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. (ekstern lenke)

2013

• Gro Gausdal; Anita Wergeland; Jørn Skavland et al. (2013). Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. (ekstern lenke)
• Øystein Helland; Katharina Bishof; Mihaela Lucia Popa et al. (2013). Histone deacetylase inhibisjon i kombinasjon med platinum i en klinisk relevant ortotopisk musemodel for ovarialcancer. (ekstern lenke)
• Øystein Helland; Mihaela Lucia Popa; Bjørn Tore Gjertsen et al. (2013). Panobinostat / carboplatin delay postsurgical relapse of ovarian carcinomas in an orthotopic mouse model. (ekstern lenke)
• Emmet McCormack; Katherine J. Adams; Namir J. Hassan et al. (2013). Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. (ekstern lenke)
• Bjørn Tore Gjertsen (2013). Phosphoprotein signaling in acute myeloid leukemia. (ekstern lenke)
• Hanne Kristin Fredly; Elisabeth Ersvær; Astrid Marta Olsnes Kittang et al. (2013). The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. (ekstern lenke)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Dag Hoem et al. (2013). Ultrasound-assisted treatment of an inoperable pancreatic cancer. (ekstern lenke)
• Ola Kristoffer Øye; Katarina Mariann Jørgensen; Sigrun Margrethe Hjelle et al. (2013). Gel2DE-A software tool for correlation analysis of 2D gel electrophoresis data. (ekstern lenke)
• Martine Müller Kloster; Elin Hallan Naderi; Ingvild Haaland et al. (2013). cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. (ekstern lenke)
• Hanne Kristin Fredly; Elisabeth Ersvær; Astrid Marta Olsnes Kittang et al. (2013). The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. (ekstern lenke)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Dag Hoem et al. (2013). Ultrasound-assisted treatment of an inoperable pancreatic cancer. (ekstern lenke)
• Håkon Reikvam; Ina Nepstad; Andre Sulen et al. (2013). Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. (ekstern lenke)
• Emmet McCormack; Maja Mujic; Tereza Osdal et al. (2013). Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. (ekstern lenke)
• Maja Mujic; Ragnhild Haugse; Spiros Kotopoulis et al. (2013). Ultrasound combined with microbubbles modulates signal transduction pathways in blood cells. (ekstern lenke)
• Hanne Kristin Fredly; Bjørn Tore Gjertsen; Øystein Bruserud (2013). Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. (ekstern lenke)
• Tea Pemovska; Mika Kontro; Bhagwan Yadav et al. (2013). Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. (ekstern lenke)
• Øystein Helland; P. Mihaela; Bjørn Tore Gjertsen et al. (2013). PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. (ekstern lenke)
• Spiros Kotopoulis; Anthony Delalande; Mihaela Popa et al. (2013). Ultrasound and microbubble enhanced therapy of orthotopic human pancreatic cancer in mice. (ekstern lenke)
• Emmet McCormack; Elisabeth Silden; Richard M. West et al. (2013). Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. (ekstern lenke)
• Lars Herfindal; Lene Elisabeth Myhren; Bjørn Tore Gjertsen et al. (2013). Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. (ekstern lenke)

2021

• Ellen Færgestad Mosleth; Christian Alexander Vedeler; Kristian Hovde Liland et al. (2021). Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. (ekstern lenke)
• Jeroen Janssen; Bob Löwenberg; Markus Manz et al. (2021). Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds. (ekstern lenke)
• Shamundeeswari Anandan; Liv Cecilie Vestrheim Thomsen; Stein-Erik Gullaksen et al. (2021). Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. (ekstern lenke)
• Oddmund Nordgård; Rakel Brendsdal Forthun; Morten Lapin et al. (2021). Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. (ekstern lenke)
• Robert J. Kreitman; Claire Dearden; Pier Luigi Zinzani et al. (2021). Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. (ekstern lenke)
• Shamundeeswari Anandan; Liv Cecilie Vestrheim Thomsen; Stein-Erik Gullaksen et al. (2021). Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. (ekstern lenke)
• Oddmund Nordgård; Rakel Brendsdal Forthun; Morten Lapin et al. (2021). Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. (ekstern lenke)
• Sahba Shafiee; Pascal Francois Gelebart; Mihaela-Lucia Popa et al. (2021). Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. (ekstern lenke)
• Ingvild Haaland; Sigrun Margrethe Hjelle; Håkon Reikvam et al. (2021). p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. (ekstern lenke)
• Caroline Engen; Monica Hellesøy; Tim Grob et al. (2021). FLT3-ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. (ekstern lenke)
• Kristine Yttersian Sletta; Oriol Castells Marin; Bjørn Tore Gjertsen (2021). Colony stimulating factor 1 receptor in acute myeloid leukemia. (ekstern lenke)
• Edvin Tang Gundersen; Jan-Lukas Førde; Benedicte Sjo Tislevoll et al. (2021). Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation. (ekstern lenke)
• Neha Rana; Salwa Suliman; Samih Salah Eldin Mahgoub Mohamed-Ahmed et al. (2021). Systemic monocyte-macrophage response to co-transplanting mesenchymal stromal cells and biphasic calcium phosphate biomaterial for bone regeneration. (ekstern lenke)
• Lok Lam Ngai; Connie Y. Ma; Orla Maguire et al. (2021). Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. (ekstern lenke)
• Neha Rana; Salwa Suliman; Samih Salah Eldin Mahgoub Mohamed-Ahmed et al. (2021). Systemic and local innate immune responses to surgical co-transplantation of mesenchymal stromal cells and biphasic calcium phosphate for bone regeneration. (ekstern lenke)
• Thierry Jaffredo; Alessandra Balduini; Anna Bigas et al. (2021). The eha research roadmap: normal hematopoiesis. (ekstern lenke)
• Silje Johansen; Ingvild Jenssen Lægreid; Siw Leiknes Ernstsen et al. (2021). Thrombosis and thrombocytopenia after HPV vaccination. (ekstern lenke)
• Katerina Bakunina; Hein Putter; Jurjen Versluis et al. (2021). The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. (ekstern lenke)

2014

• Sonia Gavasso; Ellen Færgestad Mosleth; Tove Helene Marøy et al. (2014). Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. (ekstern lenke)
• David A. Rizzieri; Norbert Vey; Xavier Thomas et al. (2014). A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. (ekstern lenke)
• M Kontro; H Kuusanmäki; S Eldfors et al. (2014). Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. (ekstern lenke)
• Bjørn Tore Gjertsen (2014). Mot en mer spesifikk kreftbehandling? :. (ekstern lenke)
• Johannes Landskron; Øystein Helland; Knut Martin Torgersen et al. (2014). Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. (ekstern lenke)
• M Kontro; H Kuusanmäki; S Eldfors et al. (2014). Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. (ekstern lenke)
• Bjørn Tore Gjertsen (2014). Mot en mer spesifikk kreftbehandling? :. (ekstern lenke)
• Johannes Landskron; Øystein Helland; Knut Martin Torgersen et al. (2014). Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. (ekstern lenke)
• Øystein Helland; Mihaela Lucia Popa; Olav Karsten Vintermyr et al. (2014). First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. (ekstern lenke)
• Spiros Kotopoulis; Ragnhild Haugse; Maja Mujic et al. (2014). Evaluation of the effects of clinical diagnostic ultrasound in combination with ultrasound contrast agents on cell stress: Single cell analysis of intracellular phospho-signaling pathways in blood cancer cells and normal blood leukocytes. (ekstern lenke)
• Caroline Benedicte Nitter Engen; Line Wergeland; Jørn Skavland et al. (2014). Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. (ekstern lenke)
• Spiros Kotopoulis; Anthony Delalande; Mihaela Lucia Popa et al. (2014). Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. (ekstern lenke)
• Ling Li; Tereza Osdal; Yinway Ho et al. (2014). SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. (ekstern lenke)
• Peter Hampson; Keqing Wang; Elisabeth Ersvær et al. (2014). Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukemic compound PEP005 in primary AML cells. (ekstern lenke)

2015

• Spiros Kotopoulis; Mihaela Lucia Popa; MJ Safont et al. (2015). Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume.. (ekstern lenke)
• Herschel Mukherjee; Kok-Ping Chan; Vibeke Andresen et al. (2015). Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. (ekstern lenke)
• Herschel Mukherjee; Kok-Ping Chan; Vibeke Andresen et al. (2015). Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. (ekstern lenke)
• Johannes Landskron; Øystein Helland; Knut Martin Torgersen et al. (2015). Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. (ekstern lenke)
• Øystein Bruserud; Håkon Reikvam; Hanne Kristin Fredly et al. (2015). Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. (ekstern lenke)
• Henrik Hjorth-Hansen; Leif Stenke; Stina Söderlund et al. (2015). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). (ekstern lenke)
• Spiros Kotopoulis; Mihaela Lucia Popa; MJ Safont et al. (2015). Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume.. (ekstern lenke)
• Ola Myklebost; Ragnhild A Lothe; Bjørn Tore Gjertsen et al. (2015). Bør hver kreftpasient bli et eget forskningsprosjekt?. (ekstern lenke)
• Bjørn Tore Gjertsen; Patrick Schöffski (2015). Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. (ekstern lenke)

2005

• Elisabeth Anne Okumu Dimba; Therese Bredholt; Bjørn Tore Gjertsen et al. (2005). Khat- and cathionine-induced apoptosis is modulated by Bcl-2 protein expression. (ekstern lenke)
• Therese Bredholt; Elisabeth Anne Okumu Dimba; K.O. Fossan et al. (2005). Molecular mechanisms of apoptosis induced by khat extract and its alkaloids cathinone and cathine in acute myeloid leukemia. (ekstern lenke)
• Anita Ryningen; Line Wergeland; Nils Glenjen et al. (2005). In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. (ekstern lenke)
• Trond Hellem Bø; Laila Stordrange; Anne Margrete Øyan et al. (2005). Analysis of treatment response in acute myeloid leukemia patients using DNA microarrays. (ekstern lenke)
• Anita Ryningen; Line Wergeland; Nils Glenjen et al. (2005). In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. (ekstern lenke)
• Trond Hellem Bø; Laila Stordrange; Anne Margrete Øyan et al. (2005). Analysis of treatment response in acute myeloid leukemia patients using DNA microarrays. (ekstern lenke)
• Kimberley Joanne Hatfield; Astrid Marta Olsnes; Bjørn Tore Gjertsen et al. (2005). Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. (ekstern lenke)
• Bjørn Tore Gjertsen (2005). Single cell profiling of potentiated phospho-protein networks in cancer cells. (ekstern lenke)
• Gry Sjøholt; Nina Ånensen; Line Wergeland et al. (2005). Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. (ekstern lenke)
• Elisabeth Anne Okumu Dimba; Therese Bredholt; Daniela-Elena Costea et al. (2005). Mechanisms of apoptosis induction by khat alkaloids in leukaemia cells. (ekstern lenke)
• Laila Stordrange; Anne Margrete Øyan; Bjørn Tore Gjertsen et al. (2005). Discovering candidate genes that distinguish between CML and AML using microarrays. (ekstern lenke)
• Anne Margrete Øyan; Trond Hellem Bø; Inge Jonassen et al. (2005). CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. (ekstern lenke)
• Emmet Martin McCormack; Øystein Bruserud; Bjørn Tore Gjertsen (2005). Animal models of acute myelogenous leukaemia - development, application and future perspectives. (ekstern lenke)
• Gry Sjøholt; Nina Ånensen; Line Wergeland et al. (2005). Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. (ekstern lenke)

2010

• Kimberley Joanne Hatfield; Siv Lise Bedringaas; Bjørn Tore Gjertsen et al. (2010). OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. (ekstern lenke)
• Kimberley Joanne Hatfield; Siv Lise Bedringaas; Anita Ryningen et al. (2010). Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. (ekstern lenke)
• Sigrun Margrethe Hjelle; Rakel Brendsdal Forthun; Ingvild Haaland et al. (2010). Clinical proteomics of myeloid leukemia. (ekstern lenke)
• Christine Gjerdrum; Crina Elena Tiron; Torill Høiby et al. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. (ekstern lenke)
• Elisabeth Ersvær; Knut Liseth; Jørn Skavland et al. (2010). Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. (ekstern lenke)

2004

• Sigbjørn Berentsen; Elling Ulvestad; Bjørn Tore Gjertsen et al. (2004). Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. (ekstern lenke)
• J.M. Irish; R. Hovland; P.O. Krutzik et al. (2004). Single cell profiling of potentiated phospho-protein networks in cancer cells. (ekstern lenke)
• Bjørn Tore Gjertsen; Øystein Bruserud (2004). How should clinical data be included in experimental studies of cancer immunology?. (ekstern lenke)
• Øystein Bruserud; Anita Ryningen; Line Wergeland et al. (2004). Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. (ekstern lenke)
• Elisabeth Ersvær; Liv-Turid Bertelsen; Lars Christian Espenes et al. (2004). Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease. (ekstern lenke)
• Sigbjørn Berentsen; Elling Ulvestad; Bjørn Tore Gjertsen et al. (2004). Rituximab for pimary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. (ekstern lenke)
• Gro Gausdal; Bjørn Tore Gjertsen; Kari Espolin Fladmark et al. (2004). Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. (ekstern lenke)
• E.A. Dimba; Bjørn Tore Gjertsen; Therese Bredholt et al. (2004). Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukaemia cells. (ekstern lenke)

2012

• Nina Ånensen; Sigrun Margrethe Hjelle; Belle Werner Van et al. (2012). Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. (ekstern lenke)
• Galina Tsykunova; Håkon Reikvam; Aymen B Ahmed et al. (2012). Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia?. (ekstern lenke)
• Sonia Gavasso; Bjørn Tore Gjertsen; Endre Anderssen et al. (2012). Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. (ekstern lenke)
• Stein-Erik Uriarte Gullaksen; Alexandre Micoulet; Bjørn Tore Gjertsen (2012). Deformation of acute myeloid leukaemia cells in micro-constriction array; a novel tool to study cell stress signalling. (ekstern lenke)
• Roger Bjugn; Bjørn Tore Gjertsen (2012). Humane celler og helseforskningsloven. (ekstern lenke)
• Sonia Gavasso; Bjørn Tore Gjertsen; Endre Anderssen et al. (2012). Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. (ekstern lenke)
• Maja Mujic; Spiros Kotopoulis; Anthony Delalande et al. (2012). Flow cytometic characterization and sorting of ultrasound contrast agents. (ekstern lenke)
• Bjørn Tore Gjertsen; Helge Wiig (2012). Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. (ekstern lenke)
• Philip Hallenborg; Søren Feddersen; Sarah Francoz et al. (2012). Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. (ekstern lenke)
• Øystein Helland; Mihaela Lucia Popa; Olav Karsten Vintermyr et al. (2012). Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. (ekstern lenke)
• Sonia Gavasso; Tove Helene Marøy; Ellen Færgestad Mosleth et al. (2012). Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. (ekstern lenke)
• Sigrun Margrethe Hjelle; Andre Sulen; Ola Kristoffer Øye et al. (2012). Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. (ekstern lenke)
• Francis Giles; François-Xavier Mahon; Bjørn Tore Gjertsen et al. (2012). Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. (ekstern lenke)
• David A. Rizzieri; Norbert Vey; Xavier Thomas et al. (2012). A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. (ekstern lenke)
• Anthony Delalande; Spiros Kotopoulis; Chantal Pichon et al. (2012). Microbubbles and cell interactions. (ekstern lenke)

2019

• Ragnhild Haugse; Anika Langer; Stein-Erik Gullaksen et al. (2019). Intracellular signaling in key pathways is induced by treatment with ultrasound and microbubbles in a leukemia cell line, but not in healthy peripheral blood mononuclear cells. (ekstern lenke)
• Frida Johanne Lundevall; Siv Lise Bedringaas; Karl Wilhelm Törnroos et al. (2019). Synthesis and investigation of Ag-NHC complexes with cytotoxic properties towards cell lines modelling acute myeloid leukemia. (ekstern lenke)
• Vibeke Andresen; Bjørn Tore Gjertsen (2019). Clinical trials of repurposing medicines in acute myeloid leukemia: Limitations and possibilities in the age of precision therapy. (ekstern lenke)
• Rakel Brendsdal Forthun; Randi Hovland; Cornelia Schuster et al. (2019). ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. (ekstern lenke)
• Ida Sofie Grønningsæter; Hanne Kristin Fredly; Bjørn Tore Gjertsen et al. (2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.. (ekstern lenke)
• Katharina Bischof; Stian Knappskog; Sigrun Margrethe Hjelle et al. (2019). Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. (ekstern lenke)
• Frida Johanne Lundevall; Siv Lise Bedringaas; Karl Wilhelm Törnroos et al. (2019). Synthesis and investigation of Ag-NHC complexes with cytotoxic properties towards cell lines modelling acute myeloid leukemia. (ekstern lenke)
• Vibeke Andresen; Bjørn Tore Gjertsen (2019). Clinical trials of repurposing medicines in acute myeloid leukemia: Limitations and possibilities in the age of precision therapy. (ekstern lenke)
• Rakel Brendsdal Forthun; Randi Hovland; Cornelia Schuster et al. (2019). ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. (ekstern lenke)
• Ida Sofie Grønningsæter; Hanne Kristin Fredly; Bjørn Tore Gjertsen et al. (2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.. (ekstern lenke)
• Andrea Gras Navarro; Heidi Espedal; Justin Vareecal Joseph et al. (2019). Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. (ekstern lenke)
• Katharina Bischof; Line Bjørge; Bjørn Tore Gjertsen et al. (2019). Rethinking Gynecological High- Grade Serous Carcinoma. Portraying the p53 isoform landscape and development of a new preclinical for optical imaging in xenograft models. (ekstern lenke)
• Mohummad Aminur Rahman; Andrea Gras Navarro; Jorunn Brekke et al. (2019). Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. (ekstern lenke)
• Nina Louise Jebsen; Torunn Oveland Apelseth; Hans Kristian Haugland et al. (2019). Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: A case report. (ekstern lenke)
• Anna Kreutzman; Bhagwan Yadav; Tim H. Brümmendorf et al. (2019). Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. (ekstern lenke)
• Stein-Erik Gullaksen; Lucius Bader; Monica Hellesøy et al. (2019). Titrating complex mass cytometry panels. (ekstern lenke)
• Rakel Brendsdal Forthun; Monica Hellesøy; Andre Sulen et al. (2019). Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. (ekstern lenke)

2023

• Inge G.P. Geelen; Stein-Erik Gullaksen; Mette M. Ilander et al. (2023). Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. (ekstern lenke)
• Liv Cecilie Vestrheim Thomsen; Alfred Honore; Lars Anders Rokne Reisæter et al. (2023). A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. (ekstern lenke)
• Yngvar Fløisand; Mats Remberger; Iris Bigalke et al. (2023). WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. (ekstern lenke)
• Peter Hokland; Isolda I. Fernández; Sylvie D. Freeman et al. (2023). AML in the elderly—A global view. (ekstern lenke)
• Liv Cecilie Vestrheim Thomsen; Alfred Honore; Lars Anders Rokne Reisæter et al. (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC). (ekstern lenke)
• Benedicte Sjo Tislevoll; Monica Hellesøy; Oda Helen Eck Fagerholt et al. (2023). Early response evaluation by single cell signaling profiling in acute myeloid leukemia. (ekstern lenke)
• Andreas Tvedt Skarstein; Tuyen Hoang; Hallvard Haugen et al. (2023). In vitro Study of STAT3-inhibitors in Drug-Resistant Chronic Myeloid Leukemia (CML). (ekstern lenke)
• Brunangelo Falini; Maria Paola Martelli; Lorenzo Brunetti et al. (2023). The NPM1 mutant defines AML irrespective of blast count. (ekstern lenke)
• Brunangelo Falini; Bjørn Tore Gjertsen; Vibeke Andresen (2023). The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?. (ekstern lenke)
• Liv Cecilie Vestrheim Thomsen; Alfred Honore; Bjørn Tore Gjertsen et al. (2023). A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC.. (ekstern lenke)
• Liv Cecilie Vestrheim Thomsen; Alfred Honore; Lars Anders Rokne Reisæter et al. (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC). (ekstern lenke)
• Jesse M. Tettero; Yara Buisman; Lok Lam Ngai et al. (2023). Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML. (ekstern lenke)

2008

• Bjørn Tore Gjertsen; James Lorens (2008). Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. (ekstern lenke)
• Kimberley Joanne Hatfield; Randi Hovland; Anne Margrete Øyan et al. (2008). Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. (ekstern lenke)
• Kimberley Joanne Hatfield; Randi Hovland; Anne Margrete Øyan et al. (2008). Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. (ekstern lenke)
• Bjørn Tore Gjertsen; Emmet Martin McCormack (2008). Erythropoietin a safe bet in haemorrhagic shock?. (ekstern lenke)
• Anita Ryningen; Camilla I Stapnes; Kristin Paulsen et al. (2008). In vivo biological effects of ATRA in the treatment of AML. (ekstern lenke)
• Sonia Gavasso; Jørn Skavland; Bjørn Tore Gjertsen et al. (2008). Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. (ekstern lenke)
• Emmet Martin McCormack; Øystein Bruserud; Bjørn Tore Gjertsen (2008). Review: genetic models of acute myeloid leukaemia. (ekstern lenke)

2020

• G.J. Ossenkoppele; D.A. Breems; G. Stuessi et al. (2020). Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0). (ekstern lenke)
• Therese Bredholt Onyango; Sigrun Margrethe Hjelle; Ingvild Haaland et al. (2020). A comparison of p53 isoform profiles and apoptosis induced by camptothecin or a herbal khat extract (Catha edulis (vahl) forssk. ex endl.) in leukemic cell lines: Exploring cellular responses in therapy development. (ekstern lenke)
• Andreas Hochhaus; Carlo Gambacorti-Passerini; Camille Abboud et al. (2020). Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. (ekstern lenke)
• Oda Helen Eck Fagerholt; Monica Hellesøy; Stein-Erik Gullaksen et al. (2020). Single cell detection of the p53 protein by mass cytometry. (ekstern lenke)
• Daniele Mercatelli; Massimo Bortolotti; Vibeke Andresen et al. (2020). Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling. (ekstern lenke)
• Eirin Alme; Karl Wilhelm Törnroos; Bjørn Tore Gjertsen et al. (2020). Synthesis of N-aryl- and N-alkyl-substituted imidazolium silver complexes: Cytotoxic screening by using human cell lines modelling acute myeloid leukaemia. (ekstern lenke)
• Xiang Wang; Linhong Deng; Bjørn Tore Gjertsen (2020). A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes. (ekstern lenke)
• Therese Bredholt Onyango; Sigrun Margrethe Hjelle; Ingvild Haaland et al. (2020). A comparison of p53 isoform profiles and apoptosis induced by camptothecin or a herbal khat extract (Catha edulis (vahl) forssk. ex endl.) in leukemic cell lines: Exploring cellular responses in therapy development. (ekstern lenke)
• Andreas Hochhaus; Carlo Gambacorti-Passerini; Camille Abboud et al. (2020). Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. (ekstern lenke)
• Caroline Benedicte Nitter Engen; Bjørn Tore Gjertsen; Øystein Bruserud et al. (2020). Exploring the boundaries of precision haemato-oncology : The case of FLT3 length mutated acute myeloid leukaemia. (ekstern lenke)
• Mahesh Tambe; Ella Karjalainen; Markus Vähä-Koskela et al. (2020). Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. (ekstern lenke)
• Hans-René Bjørsvik; Bjørn Tore Gjertsen; Vijayaragavan Elumalai (2020). Hit to leads with cytotoxic effect in leukemic cells: Total synthesis intermediates as a molecule treasure chest. (ekstern lenke)
• Dagim Shiferaw Tadele; Joseph Robertson; Richard Crispin et al. (2020). A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. (ekstern lenke)
• Muntasir M. Majumder; Aino-Maija Leppä; Monica Hellesøy et al. (2020). Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. (ekstern lenke)
• Ragnhild Haugse; Anika Langer; Elisa Thodesen Murvold et al. (2020). Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells. (ekstern lenke)

2016

• Øystein Helland; Mihaela Lucia Popa; Katharina Bischof et al. (2016). The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. (ekstern lenke)
• Andre Sulen; Bjørn Tore Gjertsen (2016). Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability. (ekstern lenke)
• Spiros Kotopoulis; Georg Gjorgji Dimcevski; Emmet McCormack et al. (2016). Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. (ekstern lenke)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Tormod Karlsen Bjånes et al. (2016). Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. (ekstern lenke)
• Spiros Kotopoulis; Georg Gjorgji Dimcevski; Emmet McCormack et al. (2016). Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. (ekstern lenke)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Tormod Karlsen Bjånes et al. (2016). Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. (ekstern lenke)
• Andre Sulen; Stein-Erik Gullaksen; Lucius Bader et al. (2016). Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. (ekstern lenke)
• Noortje Thielen; Johan Richter; Matthias Baldauf et al. (2016). Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. (ekstern lenke)
• Georg Gjorgji Dimcevski; Spiros Kotopoulis; Tormod Karlsen Bjånes et al. (2016). A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. (ekstern lenke)
• Spiros Kotopoulis; Georg Gjorgji Dimcevski; Emmet Mc Cormack et al. (2016). Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: A phase I clinical trial. (ekstern lenke)
• Sonia Gavasso; Stein-Erik Gullaksen; Jørn Skavland et al. (2016). Single-cell proteomics: Potential implications for cancer diagnostics. (ekstern lenke)

1996

• Bjørn Tore Gjertsen (1996). Kreftcellens skjulte veier til apotose. (ekstern lenke)
• Odd Terje Brustugun; Gunnar Mellgren; Bjørn Tore Gjertsen et al. (1996). Sensitive and rapid detection of B-galactosidase expression in intact cells by microinjection of fluorecent substrate. (ekstern lenke)

2009

• Camilla I Stapnes; Bjørn Tore Gjertsen; Håkon Reikvam et al. (2009). Targeted therapy in acute myeloid leukaemia: current status and future directions. (ekstern lenke)
• Jian Wang; Oleg Tsinkalovsky; P Zhao et al. (2009). TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. (ekstern lenke)
• Anne Margrete Øyan; Nina Ånensen; Trond Hellem Bø et al. (2009). Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. (ekstern lenke)
• Bjørn Tore Gjertsen (2009). Er høyt hemoglobinnivå farlig?. (ekstern lenke)
• Camilla I Stapnes; Bjørn Tore Gjertsen; Håkon Reikvam et al. (2009). Targeted therapy in acute myeloid leukaemia: current status and future directions. (ekstern lenke)
• Jian Wang; Oleg Tsinkalovsky; P Zhao et al. (2009). TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. (ekstern lenke)
• Thoralf Christoffersen; Tormod K. Guren; Karen-Lise Garm Spindler et al. (2009). Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. (ekstern lenke)
• Håkon Reikvam; Astrid Marta Olsnes; Bjørn Tore Gjertsen et al. (2009). Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. (ekstern lenke)
• Eystein Oveland; Bjørn Tore Gjertsen; Line Wergeland et al. (2009). Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. (ekstern lenke)
• Astrid Marta Olsnes; Elisabeth Ersvær; Anita Ryningen et al. (2009). The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. (ekstern lenke)
• Kimberley Joanne Hatfield; Anne Margrete Øyan; Elisabeth Ersvær et al. (2009). Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. (ekstern lenke)
• Anita Ryningen; Camilla I Stapnes; Philippe Lassalle et al. (2009). A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. (ekstern lenke)

2024

• Kristin Bentung Lygre; Rakel Brendsdal Forthun; Trude Høysæter et al. (2024). Assessment of postoperative circulating tumour DNA to predict early recurrence in patients with stage I–III right-sided colon cancer: prospective observational study. (ekstern lenke)
• Vincent Cuminetti; Joanna Konieczny; Aurora Bernal Mera et al. (2024). Succinate receptor 1 signaling regulates hematopoiesis via S100/a8 and S100/a9 in health and malignancy. (ekstern lenke)
• Kristin Bentung Lygre; Rakel Brendsdal Forthun; Trude Høysæter et al. (2024). Assessment of postoperative circulating tumour DNA to predict early recurrence in patients with stage I–III right-sided colon cancer: prospective observational study. (ekstern lenke)
• Dimitrios Kleftogiannis; Sonia Gavasso; Benedicte Sjo Tislevoll et al. (2024). Automated cell type annotation and exploration of single-cell signaling dynamics using mass cytometry. (ekstern lenke)
• Kari Hemminki; Frantisek Zitricky; Asta Försti et al. (2024). Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century. (ekstern lenke)
• Alesia A. Khan; Daniel James; Vibeke Andresen et al. (2024). Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations. (ekstern lenke)
• Benjamin William Caulier; Sandy Joaquina; Pascal Francois Gelebart et al. (2024). CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. (ekstern lenke)
• Åslaug Helland; Eli Sihn Samdal Steinskog; Egil Støre Blix et al. (2024). Hever kvaliteten på behandling av kreft. (ekstern lenke)
• Alessandra Venanzi; Valeria Cardinali; Vincenzo Perriello et al. (2024). Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia. (ekstern lenke)
• Trung Quang Ha; Vibeke Andresen; Bjarte Skoe Erikstein et al. (2024). Preclinical activity of resazurin in acute myeloid leukaemia. (ekstern lenke)
• Hjalmar Flygt; Stina Söderlund; Johan Richter et al. (2024). Correction to: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial (Leukemia, (2024), 10.1038/s41375-024-02145-6). (ekstern lenke)

1998

• Mihaela Roxana Cimpan; Bjørn Tore Gjertsen; Nils Skaug et al. (1998). A comparative study of cytopathogenic effects of four denture base acrylic resins. (ekstern lenke)
• Joar Austad; Jens Roar Bjerke; Bjørn Tore Gjertsen et al. (1998). Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. (ekstern lenke)
• Mihaela Roxana Cimpan; Bjørn Tore Gjertsen; Nils Skaug et al. (1998). A comparative study of cytopathogenic effects of four denture base acrylic resins. (ekstern lenke)
• Odd Terje Brustugun; Kari Espolin Fladmark; Gunnar Mellgren et al. (1998). Ultrarapid apoptosis induction in a variety of cell types injected with phosphatase inhibitors is mediated through Ca2 /calmodulin dependent protei kinase activity. (ekstern lenke)

2018

• Katharina Bischof; Stian Knappskog; Ingunn Stefansson et al. (2018). High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. (ekstern lenke)
• Ina Nepstad; Kimberley Joanne Hatfield; Elise Aasebø et al. (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. (ekstern lenke)
• Jorunn Kirkeleit; Trond Riise; Tone Bjørge et al. (2018). Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study. (ekstern lenke)
• Katharina Bischof; Stian Knappskog; Ingunn Stefansson et al. (2018). High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. (ekstern lenke)
• Stein-Erik Gullaksen; Bjørn Tore Gjertsen; Jorunn Kirkeleit et al. (2018). Single cell signalling and immune profiles in chronic myeloid leukaemia. (ekstern lenke)
• Katarina Mariann Jørgensen; Ellen Færgestad Mosleth; Kristian Hovde Liland et al. (2018). Gene expression response in peripheral blood cells of petroleum workers exposed to sub-ppm benzene levels. (ekstern lenke)
• Marte Karen Brattås; Kyrre Flattun Lilleeng; Randi Hovland et al. (2018). Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. (ekstern lenke)
• Cecilie Gudveig Gjerde; Kamal Babikeir Eln Mustafa; Sølve Hellem et al. (2018). Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial.. (ekstern lenke)
• Maria Omsland; Cynthia A. Pise-Masison; Dai Fujikawa et al. (2018). Inhibition of tunneling nanotube (TNT) formation and Human T-cell leukemia virus type 1 (HTLV-1) transmission by cytarabine. (ekstern lenke)
• Håkon Reikvam; Jørn Skavland; Stein-Erik Gullaksen et al. (2018). Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. (ekstern lenke)
• Robert J. Kreitman; Claire Dearden; Pier Luigi Zinzani et al. (2018). Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. (ekstern lenke)

2022

• Jani Huuhtanen; Mette Ilander; Bhagwan Yadav et al. (2022). IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. (ekstern lenke)
• Giulia Pianigiani; Francesca Rocchio; Sara Peruzzi et al. (2022). The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. (ekstern lenke)
• Jani Huuhtanen; Mette Ilander; Bhagwan Yadav et al. (2022). IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. (ekstern lenke)
• Kjetil Tasken; Hege Elisabeth Giercksky Russnes; Eline Aas et al. (2022). A national precision cancer medicine implementation initiative for Norway. (ekstern lenke)
• Jesse M. Tettero; Waleed K. W. Al-Badri; Lok Lam Ngai et al. (2022). Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. (ekstern lenke)
• Dimitrios Kleftogiannis; Benedicte Sjo Tislevoll; Monica Hellesøy et al. (2022). Identifying predictors of survival in patients with leukemia using single-cell mass cytometry and machine learning. (ekstern lenke)
• Benedicte Sjo Tislevoll; Monica Hellesøy; Oda Helen Eck Fagerholt et al. (2022). Early response evaluation by single cell signaling profiling in acute myeloid leukemia. (ekstern lenke)
• Astrid Bjørke Jenssen; Samih Salah Eldin Mahgoub Mohamed-Ahmed; Esko Kankuri et al. (2022). Administration Methods of Mesenchymal Stem Cells in the Treatment of Burn Wounds. (ekstern lenke)
• Åslaug Helland; Hege Elisabeth Giercksky Russnes; Gro Live Fagereng et al. (2022). Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. (ekstern lenke)

2011

• Hanne Kristin Fredly; Elisabeth Ersvær; Bjørn Tore Gjertsen et al. (2011). Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. (ekstern lenke)

2000

• Øystein Bruserud; Bjørn Tore Gjertsen; Hilde L von Volkman (2000). In vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. (ekstern lenke)
• Mihaela Roxana Cimpan; Lill Irene Cressey; Nils Skaug et al. (2000). Patterns of cell death induced by eluates from denture base acrylic resins in U-937 human monoblastoid cells. (ekstern lenke)

1994

• Bjørn Tore Gjertsen (1994). Multiple apoptotic death types induced via separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. (ekstern lenke)
• Bjørn Tore Gjertsen; L. I. Cressey; S. Ruchaud et al. (1994). Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. (ekstern lenke)

1997

• Bjørn Tore Gjertsen; Øystein Vatne; Arvid E Nilsen (1997). Hudsykdommer. 2. utgave. (ekstern lenke)
• Kari Espolin Fladmark; Bjørn Tore Gjertsen; Anders Molven et al. (1997). Gap junctions and growth control in liver regeneration and in isolated rat hepatocytes. (ekstern lenke)

1999

• Kari Espolin Fladmark; Odd Terje Brustugun; Randi Hovland et al. (1999). Ultrarapid apoptosis inducted by phosphatase inhibitors. Cell Death Differ. (ekstern lenke)
• Mihaela Roxana Cimpan; Nils Skaug; Bjørn Tore Gjertsen et al. (1999). Altered clonogenicity and induction of apoptotic cell death in L929 cells exposed to denture base acrylic resins. (ekstern lenke)

1993

• Stein Ove Døskeland; Bjørn Tore Gjertsen; G. Houge et al. (1993). Signal-induced Apoptosis in Myeloid Leukemia. Apoptosis or Programmed Cell Death. From Basic Research to Clinical Application. (ekstern lenke)
• Bjørn Tore Gjertsen; E. Duprez; O. Bernard et al. (1993). Anti-apoptotic effect of heterozygously expressed mutant RI (Ala%3%3%6 ->Asp) subunit of cAMP-kinase I in a rat leukaemia cell line. (ekstern lenke)
• G. Houge; Stein Ove Døskeland; Bjørn Tore Gjertsen (1993). Apoptotisk celledød. (ekstern lenke)
• Bjørn Tore Gjertsen; L. I. Cressey; G. Houge et al. (1993). "Cyclic AMP dependent protein kinase and phosphatase inhibitors induces different phenotypic forms of cell death.". (ekstern lenke)
• G. Houge; L. I. Cressey; Bjørn Tore Gjertsen (1993). Apoptosisk celledød - finnes det fornuft i fragmenteringen?. (ekstern lenke)
• Stein Ove Døskeland; E. Maronde; Bjørn Tore Gjertsen (1993). The genetic subtypes of cAMP-dependent protein kinase - functionally different or redundant?. (ekstern lenke)

1995

• Bjørn Tore Gjertsen (1995). cAMP-dependent protein kinase: Its regulation and its role in apoptosis of a promyelocytic leukemia cell line. (ekstern lenke)

2003

• Øystein Bruserud; Randi Hovland; Line Wergeland et al. (2003). Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.

1. Omsland M, Vibeke Andresen V, Gullaksen SE, Ayuda-Durán P, Popa M, Hovland R, Brendehaug A, Enserink J, McCormack E, Gjertsen BT. Interferon alpha and tyrosine kinase inhibitors increase tunneling nanotubes (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines. FASEB J. 2020 34(3):3773-3791. Citations: 3. IF 5.191. ••Impact: The first report on upregulation of TNT by kinase inhibitors and indicate that the old anti-leukemic interferon-alpha act share the same mechanism as kinase inhibitors. The effect of kinase inhibitor on TNT is an example of functional regulation by small molecules.

 

2.  Gullaksen SE, Skavland J, …, Gjertsen BT. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukaemia treated with nilotinib. Haematologica 2017; 102:1361-1367. Citations: 13. IF 5.814. •••Impact: This paper introduces mass cytometry panel as a core technology for single cell monitoring in clinical trials. Prognostication based on single cell analysis at 7 days indicate molecular response (tumour load) at 18 months on targeted therapy that predispose to cardiovascular disease.

 

3. Engen C, Hellesøy M, Grob T, Löwenberg B, Valk PJM, Gjertsen BT. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Mol Oncol. 2021 Jun 8. doi: 10.1002/1878-0261.13035. Citations: 0. IF 6.603. ••Impact: Prognostication based on FLT3 genetics seems only to be valid for females. Leukaemia cell samples are distinct in females and males in terms of gene expression and ex vivo drug sensitivity, in addition to the previously known sex depended mutational profile of leukaemia.

 

4. Engen C, Hellesøy M, Grob T, Hinai AA, Brendehaug A, Wergeland L, Bedringaas SL, Hovland R, Valk PJM, Gjertsen BT. FLT3-ITD mutations in acute myeloid leukaemia - Molecular characteristics, distribution and numerical variation. Mol Oncol. 2021 Apr 5. doi: 10.1002/1878-0261.12961. Citations: 0. IF 6.603. •Impact: This report demonstrates the heterogeneity of FLT3 mutations in AML, and raise a question about more accurate tools for therapy monitoring for varying cell populations in the same patient.

 

5. Forthun RB, Aasebø E, Rasinger JD, Bedringaas SL, Berven F, Selheim F, Bruserud Ø, Gjertsen BT. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. J Proteomics. 2018 Feb 20;173:32-41. Citations: 7. IF 3.537. ••Impact: Underpinning data on signaling networks affected by the phenotypes and genetics in AML.

 

6. McCormack E, Mujic M, Osdal T, Bruserud Ø, Gjertsen BT. Multiplexed monoclonal antibodies: A new strategy in preclinical time domain imaging of acute myeloid leukemia. Citations: 15. IF 9.060. Blood. 2013;121:e34-42. Impact: outline in vivo multiplexing imaging in leukemia. •••Impact: Seminal paper that point in the direction of multiplex analysis in medical imaging.

             

7. Sulen A, Lygre SH, Hjelle SM, Hollund BE, Gjertsen BT. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Sci Rep. 2016 Jul 6;6:29060. Citations: 1. IF 4.259. ••Impact: Demonstrate that single cell signaling profiling in a cross-sectional healthy survey can be used to examine exposure to smoke and correlate with occupational activity of exposure.

 

8. McCormack E, Haaland I, …, Gjertsen BT. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012 May;26(5):910-7. Citations: 63. IF 11.528. •Impact: Developing low toxicity combination and use of protein biomarkers to monitor therapy response.  

 

9. Andresen V, …, Gjertsen BT. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis. 2016 Dec 1;7(12):e2497. Citations: 8. IF 5.965. •Impact: Targeted therapy concept that point in the direction of functional diagnostics.

 

10. Ånensen N, ..., Gjertsen BT. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 2012;31(12):1533-45. Citations: 44. IF 5.965. •••Impact: First report on protein p53 isoform analysis in prognostication demonstrating consistency between p53 isoform profiles, genomics, therapy response and survival in AML.